IDH1 and central nervous system cancer: This conclusion is strongly supported by the observation that isocitrate dehydrogenase (IDH1 and IDH2) mutations are present in the majority of WHO II and III gliomas and secondary glioblastomas, but not in primary glioblastomas [94].